[1]付大鹏.托瑞米芬联合他莫昔芬应用于晚期乳腺癌的疗效[J].医学信息,2020,33(04):139-140.[doi:10.3969/j.issn.1006-1959.2020.04.044]
　FU Da-peng.Analysis of the Efficacy of Toremifene Combined with Tamoxifen in Advanced Breast Cancer[J].Medical Information,2020,33(04):139-140.[doi:10.3969/j.issn.1006-1959.2020.04.044]
点击复制

托瑞米芬联合他莫昔芬应用于晚期乳腺癌的疗效()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年04期
页码:
139-140
栏目:
药物与临床
出版日期:
2020-02-15

文章信息/Info

Title:
Analysis of the Efficacy of Toremifene Combined with Tamoxifen in Advanced Breast Cancer
文章编号:
1006-1959（2020）04-0139-02
作者:
付大鹏
（解放军联勤保障部队九六七医院肿瘤科，辽宁 大连 116000）
Author(s):
FU Da-peng
(Department of Oncology,967 Hospital of PLA Joint Service,Dalian 116000,Liaoning,China)
关键词:
托瑞米芬; 他莫昔芬; 晚期乳腺癌; 生存质量
Keywords:
Toremifene; Tamoxifen; Advanced breast cancer; Quality of life
分类号:
R737.9
DOI:
10.3969/j.issn.1006-1959.2020.04.044
文献标志码:
A
摘要:
目的 观察晚期乳腺癌患者采用托瑞米芬联合他莫昔芬的治疗效果并分析患者生存质量。方法 选取2017年5月~2018年10月在我院诊治的90例晚期乳腺癌患者为研究对象，采用随机数字表法分为对照组和观察组，各45例。对照组采用常规化疗方案，观察组在对照组基础上应用托瑞米芬联合他莫昔芬治疗，比较两组临床总有效率、治疗前后生存质量评分及毒副反应。 结果 观察组总有效率为71.11%，高于对照组的51.11%（P＜0.05）；治疗后两组生存质量评分均高于治疗前，且观察组高于对照组（P＜0.05）；两组毒副反应发生率比较，差异无统计学意义（P＞0.05）。结论 晚期乳腺癌采用托瑞米芬联合他莫昔芬治疗，有助于提高治疗疗效，改善患者生存质量，且不会增加毒副反应，安全可靠。
Abstract:
Objective To observe the therapeutic effect of toremifene combined with tamoxifen on advanced breast cancer and analyze the quality of life of patients. Methods 90 patients with advanced breast cancer diagnosed and treated in our hospital from May 2017 to October 2018 were selected as the research subjects. They were divided into control group and observation group by using the random number table method, with 45 cases in each group. The control group was treated with conventional chemotherapy, and the observation group was treated with toremifene combined with tamoxifen on the basis of the control group. The total clinical effectiveness, quality of life scores before and after treatment, and toxic and side effects were compared between the two groups. Results The total effective rate in the observation group was 71.11%, which was higher than 51.11% in the control group(P<0.05). The quality of life scores of the two groups after treatment were higher than before the treatment, and the observation group was higher than the control group(P<0.05); Comparison of the incidence of toxic and side effects between the two groups,the difference was not statistically significant(P>0.05).Conclusion The treatment of toremifene combined with tamoxifen in advanced breast cancer is helpful to improve the curative effect and improve the quality of life of patients without increasing side effects. It is safe and reliable.

参考文献/References:

[1]黎胤谋,李靖,周勇,等.他莫昔芬联合依维莫司对ER阳性转移性乳腺癌患者临床应用分析[J].药物生物技术,2018,25(2):10. [2]张保宁,陈万青,张希,等.中国乳腺癌防控形势面临挑战[J].中华肿瘤杂志,2016,38(10):798-800. [3]毕丽阳.MTDH、C-Met、TRAIL对乳腺癌化疗敏感性的研究[D].河北医科大学,2015. [4]王芬.表阿霉素联合多西紫杉醇对三阴乳腺癌新辅助化疗疗效临床观察[J].医学信息,2013,26(23):595. [5]宋强.托瑞米芬联合他莫昔芬治疗晚期乳腺癌的效果观察及对肝功能和血脂的影响[J].齐齐哈尔医学院学报,2017,38(15):1779-1781.

相似文献/References:

[1]于 东.平消片为主组合方案治疗乳腺增生症临床分析[J].医学信息,2018,31(08):136.[doi:10.3969/j.issn.1006-1959.2018.08.046]
　YU Dong.Clinical Analysis of the Combination of Pingxiao Tablets in the Treatment of Mammary Hyperplasia[J].Medical Information,2018,31(04):136.[doi:10.3969/j.issn.1006-1959.2018.08.046]

更新日期/Last Update: 2020-02-15